Evidence map›Paper›PMID 30148172›Full record

ArticleBioMed research international2018

Piotr Kupczyk, Adam Reich, Mariusz Gajda, Marcin Hołysz, Edyta Wysokińska, Maria Paprocka, Dmitry Nevozhay, Grzegorz Chodaczek, Paweł P Jagodziński, Piotr Ziółkowski and 1 more

Abstract read
In one paragraph

Article in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Piotr KupczykDepartment of Pathomorphology, Faculty of Medicine, Silesian Piast Wroclaw Medical University, Wroclaw, Poland.ORCID 0000-0002-9889-8415
Adam ReichDepartment of Dermatology, Institute of Experimental and Clinical Medicine, Faculty of Medicine, University of Rzeszow, Rzeszow, Poland.ORCID 0000-0002-5573-1754
Mariusz GajdaDepartment of Histology, Medical Collage, Jagiellonian University, Krakow, Poland.ORCID 0000-0002-3788-7528
Marcin HołyszDepartment of Biochemistry and Molecular Biology, Karol Marcinkowski Medical University of Poznan, Poznan, Poland.
Edyta WysokińskaLaboratory of Tumor Molecular Immunobiology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
Maria PaprockaLaboratory of Glycobiology and Cell Recognitions, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
Dmitry NevozhaySchool of Biomedicine, Far Eastern Federal University, Vladivostok, Russia.
Grzegorz ChodaczekConfocal Microscopy Laboratory, Wroclaw Research Centre EIT+, Wroclaw, Poland.
Paweł P JagodzińskiDepartment of Biochemistry and Molecular Biology, Karol Marcinkowski Medical University of Poznan, Poznan, Poland.ORCID 0000-0002-9046-6802
Piotr ZiółkowskiDepartment of Pathomorphology, Faculty of Medicine, Silesian Piast Wroclaw Medical University, Wroclaw, Poland.
Jacek C SzepietowskiDepartment of Dermatology, Venereology and Allergology, Silesian Piast Wroclaw Medical University, Wroclaw, Poland.ORCID 0000-0003-0766-6342

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psoriasis is an immunogenetic skin disease manifesting as plaque lesions on the skin. Patients with psoriasis frequently suffer from itch, an unpleasant sensation causing a desire to scratch. Psoriatic itch is mainly transmitted by unmyelinated C-fibers; however, the exact molecular mechanism of psoriatic itch is still unexplained. Protein gene product 9.5 (PGP 9.5) is a panneurological marker commonly used for analysis of peripheral peptidergic and nonpeptidergic nerves and identification of cutaneous neuro-immune-endocrine cells. However, some studies suggested that nonneuronal cells, like keratinocytes, may also express PGP 9.5. This phenomenon might be linked with impaired axonal transport, keratinocyte injury, or dysfunctions of neuro-immune-cutaneous connections. The aim of this study was to analyze the expression of PGP 9.5 in psoriatic skin. We observed significantly altered density of PGP 9.5-positive axonal nerve terminals in pruritic lesional (p=0.04) and nonlesional psoriatic skin (p>0.001) compared with controls. In contrast, no significant differences were observed between psoriatic skin without itch and controls. Furthermore, PGP 9.5 expression by suprabasal keratinocytes (SBKs) was significantly increased in itchy skin lesions (p=0.007) compared to skin without itch, and a positive correlation was observed between PGP 9.5 expression and itch intensity (r=0.64; p=0.02). Our findings indicate changes in peripheral innervations and psoriatic keratinocytes, which may influence neuro-immune-cutaneous homeostasis and modulate itch transmission.

Indexed as

AdultAgedEpidermisFemaleHumansKeratinocytesMaleMiddle AgedPruritusPsoriasisSkinUbiquitin ThiolesteraseYoung AdultUbiquitin ThiolesteraseUCHL1 protein, human

Identifiers

PMID30148172
PMCPMC6083486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.